1
Maher AR. Efficacy and Comparative Effectiveness of Atypical Antipsychotic Medications for Off-Label Uses in AdultsA Systematic Review and Meta-analysis. JAMA: The Journal of the American Medical Association 2011;306. doi:10.1001/jama.2011.1360
2
Clinical guidelines, CG42 - Issued: November 2006. http://guidance.nice.org.uk/CG42
3
TA217 Alzheimer’s disease - donepezil, galantamine, rivastigmine and memantine: guidance (MS Word format). http://guidance.nice.org.uk/TA217/Guidance/doc/English
4
Exelon - Summary of Product Characteristics (SPC) - (eMC). https://www.medicines.org.uk/emc/search?q=Exelon+
5
Aricept Tablets - Summary of Product Characteristics (SPC) - (eMC). http://www.medicines.org.uk/emc/medicine/577/SPC/Aricept
6
Reminyl Tablets - Summary of Product Characteristics (SPC) - (eMC).
7
Ebixa 5mg/pump actuation oral solution, 20mg and 10 mg Tablets and Treatment Initiation Pack - Summary of Product Characteristics (SPC) - (eMC). http://www.medicines.org.uk/EMC/medicine/10175/SPC/rEbxia+5mg+pump+oral+solution%252c+20mg+and+10+mg+tablets+and+Treatment+Initiation+Pack/
8
DH Living well with dementia: a National Dementia Strategy. https://www.gov.uk/government/organisations/department-of-health
9
British National Formulary. http://www.bnf.org/bnf/index.htm
10
Bhasin M, Rowan E, Edwards K, et al. Cholinesterase inhibitors in dementia with Lewy bodies—a comparative analysis. International Journal of Geriatric Psychiatry 2007;22:890–5. doi:10.1002/gps.1759
11
Kavirajan H, Schneider LS. Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials. The Lancet Neurology 2007;6:782–92. doi:10.1016/S1474-4422(07)70195-3
12
Warner J, Smith T. The rise and fall of antipsychotic prescribing in dementia. Where do we go from here? The rise and fall of antipsychotic prescribing in dementia;14:24–7.
13
Sube Banerjee. The use of antipsychotic medication for people with dementia: Time for action. A report for the Minister of State for Care Services. 12AD.http://psychrights.org/research/digest/nlps/BanerjeeReportOnGeriatricNeurolepticUse.pdf
14
Optimising treatment and care for behavioural and psychological symptoms of dementia: A best practice guide. https://www.alzheimers.org.uk/bpsdguide
15
Treatment protocol by NHS Medway: Treatment of  Behaviour That Challenges. http://www.kmpt.nhs.uk/policies
16
Antipsychotics increase mortality in elderly patients with dementia. http://www.npc.nhs.uk/merec/cns/dementia/merec_extra_no39.php
17
Electronic Medicines Compendium (eMC). http://www.medicines.org.uk/emc/
18
Pierre N. Tariot, M.D.; Rosemary Erb, R.N., B.S.N.; Carol Ann Podgorski, Ph.D.; Christopher Cox, Ph.D.; Shirish Patel, M.D.; Laura Jakimovich, M.S., R.N.; Carrie Irvine, B.A. Efficacy and Tolerability of Carbamazepine for Agitation and Aggression in Dementia. PsychiatryOnline | American Journal of Psychiatry | Efficacy and Tolerability of Carbamazepine for Agitation and Aggression in Dementia 1998;155:54–61. doi:10.1176/ajp.155.1.54
19
Martinón-Torres G, Fioravanti M, Grimley Evans J. Trazodone for agitation in dementia. Cochrane Database of Systematic Reviews Published Online First: 19 July 2004. doi:10.1002/14651858.CD004990
20
Electronic Medicines Compendium (eMC). http://www.medicines.org.uk/emc/
21
Risperdal Tablets, Liquid & Quicklet - Summary of Product Characteristics (SPC) - (eMC). http://www.medicines.org.uk/emc/document.aspx?documentid=12818&docType=SPC
22
Maher AR, Maglione M, Bagley S, et al. Efficacy and Comparative Effectiveness of Atypical Antipsychotic Medications for Off-Label Uses in Adults. JAMA 2011;306. doi:10.1001/jama.2011.1360
23
Complete Guide to Behavioural and Psychological symptoms of Dementia. http://www.ipa-online.org/
24
Waldemar G, Hyvärinen M, Josiassen MK, et al. Tolerability of switching from donepezil to memantine treatment in patients with moderate to severe Alzheimer’s disease. International Journal of Geriatric Psychiatry 2008;23:979–81. doi:10.1002/gps.1979
25
Electronic Medicines Compendium (eMC). https://www.medicines.org.uk/emc/
26
Evidence Search - Search Engine for Evidence in Health and Social Care. https://www.evidence.nhs.uk/
27
Evidence Search - Search Engine for Evidence in Health and Social Care. https://www.evidence.nhs.uk/
28
Map of Medicine | Home. http://www.mapofmedicine.com/
29
Medicines Information - Evidence Search - Search Engine for Evidence in Health and Social Care. https://www.evidence.nhs.uk/
30
NPC | National Prescribing Centre. https://www.guidelinesinpractice.co.uk
31
National Institute for Health and Care Excellence. http://www.nice.org.uk/
32
NICE Clinical Knowledge Summaries (CKS). http://cks.nice.org.uk/
33
Scottish Intercollegiate Guidelines Network (SIGN). http://www.sign.ac.uk/
34
Centre for Medicines Optimisation - MTRAC | Independent Medicines Review | Midlands Therapeutics Review & Advisory Committee | Centre for Medicines Optimisation | Keele University. http://centreformedicinesoptimisation.co.uk/mtrac/
35
NPC | National Prescribing Centre. https://www.guidelinesinpractice.co.uk
36
Evidence Search - Search Engine for Evidence in Health and Social Care. https://www.evidence.nhs.uk/
37
GOV.UK. https://www.gov.uk/government/organisations/department-of-health
38
Miller WR, Rollnick S. Motivational interviewing: helping people change. 3rd ed. New York: : Guilford Press 2013.
39
Prochaska JO, Norcross JC, DiClemente CC. Changing for good. New York: : William Morrow 1994.
40
Rollnick S, Mason P, Butler C. Health behavior change: a guide for practitioners. Edinburgh: : Churchill Livingstone 1999.
41
Rollnick S, Miller WR, Butler C. Motivational interviewing in health care: helping patients change behavior. New York: : Guilford Press 2008.
42
Hubley J, Copeman J, Woodall J. Practical health promotion. 2nd ed. Cambridge: : Polity Press 2013.
43
Laverack G. Health promotion practice: building empowered communities. Maidenhead: : Open University Press 2007. https://search.ebscohost.com/login.aspx?direct=true&AuthType=ip,shib&db=nlebk&AN=234222&site=ehost-live&scope=site&custid=s8454451
44
Macdowall W, Bonell C, Davies M. Health promotion practice. Maidenhead: : Open University Press 2006.
45
Walker R, Whittlesea C. Clinical pharmacy and therapeutics. 5th ed. Edinburgh: : Churchill Livingstone 2012. https://www.vlebooks.com/Product/Index/173020?page=0&startBookmarkId=-1
46
Kumar PJ, Clark ML. Kumar & Clark’s clinical medicine. 8th ed. Edinburgh: : Saunders Elsevier 2012. https://www.dawsonera.com/abstract/9780702053047
47
Greene RJ, Harris ND. Pathology and therapeutics for pharmacists: a basis for clinical pharmacy practice. 3rd ed. London: : Pharmaceutical Press 2008.
48
Coeliac disease: recognition, assessment and management  | Guidance and guidelines | NICE. https://www.nice.org.uk/guidance/ng20
49
Chronic obstructive pulmonary disease. http://cks.nice.org.uk/chronic-obstructive-pulmonary-disease
50
CPPE - Centre for Pharmacy Postgraduate Education. https://www.cppe.ac.uk/
51
Royal Pharmaceutical Society (RPS). http://www.rpharms.com/home/home.asp
52
Heart failure - chronic. http://cks.nice.org.uk/heart-failure-chronic
53
Medicines Use Review and Prescription Intervention service. http://psnc.org.uk/wp-content/uploads/2013/06/MUR-service-spec-Aug-2013-changes_FINAL.pdf
54
Service specification - New Medicine Service (NMS). http://psnc.org.uk/wp-content/uploads/2013/06/NMS-service-spec-Aug-2013-changes_FINAL.pdf
55
Commissioners and healthcare professionals - Training videos. http://healthcheck.nhs.uk/commissioners_and_providers/training/training_videos1/
56
NHS Health Check - NHS Choices. http://www.nhs.uk/Conditions/nhs-health-check/Pages/NHS-Health-Check.aspx